Please ensure Javascript is enabled for purposes of website accessibility

A Marijuana Market Most Investors Aren't Thinking About

By Keith Speights - Feb 18, 2018 at 8:18AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cannabis for cats and dogs? Yep.

The marijuana industry could be going to the dogs. 

Cornell University College of Veterinary Medicine recently announced results from a clinical study evaluating cannabinoids in dogs with osteoarthritis and multi-joint pain. The study found that dogs that received a hemp oil blend showed significant improvement over those that received placebo. A similar study is currently under way testing use of cannabinoids in cats.

There is currently plenty of excitement with legalization of medical marijuana in countries around the world and the impending legalization of recreational marijuana in Canada. But treatment of pets could be a marijuana market that most investors aren't thinking about.

Pug dog eating marijuana leaf

Image source: Getty Images.

Pet pharma on the rise

Developing pharmaceuticals for animals has rapidly become a big business. The world's largest animal health company, Zoetis (ZTS 1.35%), posted total revenue for 2017 of more than $5 billion. Merck's (MRK 1.37%) animal health segment generated revenue of nearly $3.9 billion last year.

It's not just the drugmakers that are doing well. PetMed Express (PETS -1.31%), one of the largest pet pharmacies in the U.S., has also seen sales and earnings grow significantly. 

There are several reasons behind the rise of pet pharma. The number of U.S. households with more than one pet is increasing as both younger and older Americans seek companionship from pets. Also, the growing middle-class populations in large countries such as China and India are more likely to own pets.

Keep in mind, though, that not all of the money made by the animal health industry is from products sold for pets. For example, over 55% of Zoetis' total revenue stems from its livestock products. Also, roughly two-thirds of the company's sales are for anti-infectives, parasiticides, and vaccines -- some of which aren't viable targets for cannabinoids.

Investing opportunities

Still, the results from the Cornell study indicate that there's a real possibility for cannabinoids in the pet pharmaceutical market. Some veterinarians have referred to use of cannabinoids in alleviating animal pain as "a game changer that will change the face of veterinary medicine." 

But are there opportunities for investors? The hemp-based products used in the Cornell study were made by Ellevet Sciences. The company is privately held, so it's not an option for investors right now. 

There are a handful of tiny cannabinoid-focused animal health companies with stocks traded over the counter. Tetra Bio-Pharma, for example, announced last year plans to develop cannabinoids for the veterinary market. Medical Marijuana Inc. (MJNA -0.76%) has a subsidiary, Phyto Animal Health, that focuses on developing cannabinoid products for the pet market. However, I don't view Tetra or Medical Marijuana as good candidates for many investors because of the risks associated with penny stocks.

As for the big players in animal health like Zoetis and Merck, I'm not aware of any of them bringing up the topic of researching cannabinoids. That doesn't mean they haven't considered doing so or won't develop cannabinoids down the road, though. 

Perhaps the bigger biotechs with cannabinoid programs will recognize an opportunity in the animal health market at some point. GW Pharmaceuticals (GWPH), for example, has performed quite a bit of testing of its cannabidiol (CBD) and cannabidivarin (CBDV) products with animals as a prerequisite for testing in humans. So far, though, GW hasn't hinted at exploring a potential expansion into the animal health market.

Ahead of its time

The reality is that there's a good reason most investors haven't thought about the potential marijuana market for pets. It's still a little ahead of its time.

Remember, it's taken many years for medical marijuana for humans to become more widely accepted. And while synthetic forms of cannabinoids have been approved for use in the U.S., GW Pharmaceuticals' Epidiolex appears likely to become the first FDA-approved drug that's actually made from marijuana. An FDA decision is expected by June 27. 

But will the day arrive where cannabinoids play a more important role in animal health? I think so. Sooner or later, investors will be able to profit. For now, though, marijuana investors might want to bark up a different tree.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zoetis Inc. Stock Quote
Zoetis Inc.
$174.21 (1.35%) $2.32
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$92.42 (1.37%) $1.25
PetMed Express, Inc. Stock Quote
PetMed Express, Inc.
$19.64 (-1.31%) $0.26
Medical Marijuana, Inc. Stock Quote
Medical Marijuana, Inc.
$0.01 (-0.76%) $0.00
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.